Brief Article
Copyright ©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Sep 7, 2013; 19(33): 5551-5556
Published online Sep 7, 2013. doi: 10.3748/wjg.v19.i33.5551
Effects of extended lymphadenectomy and postoperative chemotherapy on node-negative gastric cancer
Qiang Xue, Xiao-Na Wang, Jing-Yu Deng, Ru-Peng Zhang, Han Liang
Qiang Xue, Xiao-Na Wang, Jing-Yu Deng, Ru-Peng Zhang, Han Liang, Department of Gastric Cancer Surgery, Tianjin Medical University Cancer Hospital and City Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China
Author contributions: Wang XN, Zhang RP and Liang H performed the majority of experiments; Deng JY provided vital reagents and analytical tools and was also involved in editing the manuscript; Xue Q co-ordinated and provided the collection of all the human material in addition to providing financial support for this work; Xue Q designed the study and wrote the manuscript.
Correspondence to: Xiao-Na Wang, PhD, Professor, Department of Gastric Cancer Surgery, Tianjin Medical University Cancer Hospital and City Key Laboratory of Cancer Prevention and Therapy, Lake Road, Hexi District, Tianjin 300060, China. medaction@126.com
Telephone: +86-22-23340123-1061 Fax: +86-22-23559213
Received: May 21, 2013
Revised: June 24, 2013
Accepted: July 18, 2013
Published online: September 7, 2013
Abstract

AIM: To investigate the effects of extended lymphadenectomy and postoperative chemotherapy on gastric cancer without lymph node metastasis.

METHODS: Clinical data of 311 node-negative gastric cancer patients who underwent potentially curative gastrectomy with more than 15 lymph nodes resected, from January 2002 to December 2006, were analyzed retrospectively. Patients with pT4 stage or distant metastasis were excluded. We analyzed the relationship between the D2 lymphadenectomy and the 5-year survival rate among different subgroups stratified by clinical features, such as age, tumor size, tumor location and depth of invasion. At the same time, the relationship between postoperative chemotherapy and the 5-year survival rate among different subgroups were also analyzed.

RESULTS: The overall 5-year survival rate of the entire cohort was 63.7%. The 5-year survival rate was poor in those patients who were: (1) more than 65 years old; (2) with tumor size larger than 4 cm; (3) with tumor located in the upper portion of the stomach; and (4) with pT3 tumor. The survival rate was improved significantly by extended lymphadenectomy only in patients with pT3 tumor (P = 0.019), but not in other subgroups. Moreover, there was no significant difference in survival rate between patients with and without postoperative chemotherapy among all of the subgroups (P > 0.05).

CONCLUSION: For gastric cancer patients without lymph node metastasis, extended lymphadenectomy could improve the survival rate of those who have pT3-stage tumor. However, there was no evidence of a survival benefit from postoperative chemotherapy alone.

Keywords: Gastric cancer, Lymph node negative metastasis, Extended lymphadenectomy, D2 lymphadenectomy, Chemotherapy

Core tip: Little information is available regarding the effects of D2 lymphadenectomy and postoperative chemotherapy in patients with node-negative early gastric cancer. Data of 311 gastric cancer patients without lymph node metastasis were analyzed retrospectively. Results showed that D2 lymphadenectomy could improve the survival rate of patients with pT3-stage tumor. However, there was no evidence of a survival benefit from postoperative chemotherapy. In conclusion, it is recommended that D2 lymphadenectomy with gastrectomy be applied for node-negative patients with pT3 gastric cancer whereas the effects of postoperative chemotherapy in patients with node-negative early gastric cancer need to be further studied.